(NASDAQ: ADIL) Adial Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 61.93%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.44%.
Adial Pharmaceuticals's earnings in 2026 is -$8,051,798.On average, 4 Wall Street analysts forecast ADIL's earnings for 2026 to be -$376,797, with the lowest ADIL earnings forecast at -$479,560, and the highest ADIL earnings forecast at -$261,944. On average, 4 Wall Street analysts forecast ADIL's earnings for 2027 to be -$352,330, with the lowest ADIL earnings forecast at -$488,963, and the highest ADIL earnings forecast at -$201,496.
In 2028, ADIL is forecast to generate -$557,855 in earnings, with the lowest earnings forecast at -$535,978 and the highest earnings forecast at -$574,263.